Chemomab Therapeutics (CMMB) Accumulated Depreciation & Amortization (2020 - 2025)
Chemomab Therapeutics posted quarterly Accumulated Depreciation & Amortization of $311000.0 for Q4 2025, up 11.47% year-on-year from $279000.0 in Q4 2024, and up 11.47% on a QoQ basis from $279000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) has 6 years of Accumulated Depreciation & Amortization data on file, last reported at $311000.0 in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 11.47% year-over-year to $311000.0; the trailing twelve-month figure through Dec 2025 stood at $311000.0 (up 11.47% YoY), and the FY2025 full-year result was $311000.0, up 11.47% from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 stood at $311000.0, up from $279000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $311000.0 in Q4 2025 and bottomed at $107000.0 in Q4 2021.
- The 5-year median for Accumulated Depreciation & Amortization is $226000.0 (2023), against an average of $217600.0.
- The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization soared 54.21%; it then grew 11.47% in 2025.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $107000.0 in 2021, then jumped by 54.21% to $165000.0 in 2022, then jumped by 36.97% to $226000.0 in 2023, then gained by 23.45% to $279000.0 in 2024, then gained by 11.47% to $311000.0 in 2025.
- The last three Accumulated Depreciation & Amortization figures came in at $311000.0 (Q4 2025), $279000.0 (Q4 2024), and $226000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Dec 31, 2023 | 226,000.00 |
| Dec 31, 2023 | 226,000.00 |
| Dec 31, 2022 | 165,000.00 |
| Dec 31, 2022 | 165,000.00 |
| Dec 31, 2021 | 107,000.00 |
| Dec 31, 2021 | 107,000.00 |
| Dec 31, 2020 | 73,000.00 |
| Dec 31, 2020 | 73,000.00 |